

## Key Findings



**The global PCM market was worth \$26bn in 2007** and is expected to grow at a CAGR of 11.4% to reach \$40bn by 2011.



**Catalent is the largest CMO in the world**, with revenues of \$1.8bn in 2007. The PCM market is highly fragmented, with the top ten players in the market holding less than 30% of total market share.




**Contract manufacturing in India and China is forecast to expand at a CAGR of 20% through to 2011.** Big Pharma are increasingly outsourcing manufacturing to low cost destinations due to cost and margin pressures, and India and China offer skilled manpower and a robust manufacturing infrastructure.



**Piramal is the largest CMO in India**, and its contract manufacturing revenues increased by 33.3% in dollar terms between 2007-2008. The primary contributor to this growth was its PMS segment.



**Biopharmaceutical manufacturing is forecast to have increased by 15% in 2008**, driven by sales growth of biologics. Lonza, a leading player in this field, registered revenue growth of 75.9% in 2007.



**Figure 2.4: FDA approved plants outside the US, 2007**

"India has the largest number of FDA approved plants outside the US. GMP compliance became mandatory in India in 2005 and currently it has over 200 GMP certified facilities. India also has the highest number of Drug Master Files (DMFs), with its market share of DMFs increasing from 14% in 2000 to 46% in 2007..."

## Use this report to...

- Compare the performances of the top 10 CMO companies** across key business segments with this report's analysis of **Catalent, Lonza, Boehringer Ingelheim (BI), DSM, Patheon, Evonik, Piramal, Jubilant, Aenova, Fareva.**
- Identify the market dynamics of the global PCM industry over the 2003-07 period**, discover which emerging markets are becoming the CMO destinations of the future and understand the major issues affecting key industry players.
- Assess the future prospects of the top 10 CMO companies** with this report's analysis of each firm's manufacturing and R&D capability, growth strategies and M&A activity.
- Measure the progress of other leading CMO companies** by evaluating the financial performances of Nipro, Siegfried, Haupt, Divi's Laboratories (Divi's), Cambrex, Recipharm, Archimica, Vetter, Famar and NextPharma.

## Explore issues including...



**Increased offshore outsourcing.** Although Europe remains the biggest market for pharmaceutical outsourcing, Asia Pacific will expand rapidly over the coming years due to significant advantages over Eastern Europe and emerging countries such as Brazil, Taiwan and Korea.




**Stringent regulatory requirements.** CMOs must receive approval from international regulatory bodies such as the FDA in order to establish credibility. Such approvals are difficult to obtain and require compliance with a number of stringent norms.



**Growth of biopharma manufacturing.** Biopharmaceutical contract manufacturing is the fastest growing segment of contract manufacturing, and players in this field are expanding capacities to meet the rising demand.



**Industry consolidation.** The PCM industry is experiencing a significant amount of M&A activity due to the presence of a large number of small players. Indian companies in particular have engaged in aggressive M&A activity, with Jubilant's acquisition of DRAXIS and Hollister-Stier and Piramal's acquisition of Avecia Pharmaceuticals.



**Figure 2.2: Positioning of leading players (2007)**

"The market is dominated by six large players – Catalent, Lonza, Boehringer Ingelheim (BI), DSM, Patheon and Evonik. Of these, Lonza, BI, DSM and Evonik are large diversified pharmaceuticals and chemicals companies, while Catalent and Patheon are focused on contract services..."

## Discover...

- What are the key trends in the global PCM industry?
- Which countries are the hotspots for contract manufacturing?
- Who are the top 10 players in the industry?
- How are the top 10 players positioned?
- How will consolidation change the dynamics of the industry?
- What are the key strategies of the leading CMO companies?
- Which regions and segments offer the greatest growth opportunities?
- What is the future outlook for the industry?

## Sample Information

### Chapter 3: Catalent

#### Recent financial performance

Catalent recorded revenues of \$1,828.0m for the financial year ended June 2008, an increase of 7.3% over the previous financial year. The weaker dollar contributed approximately 6 percentage points to this increase. The remaining increase was the result of revenue growth in the Oral Technologies and Sterile Technologies segments, partially offset by a revenue decline in the Packaging Services segment. Catalent's operating loss increased from \$73.7m for the financial year 2007 to \$247.5m for the financial year 2008. This was primarily due to goodwill impairment of \$239.0m within the Packaging Services segment.

#### Oral Technologies

Revenues from the Oral Technologies segment increased 10.1% to \$1,039.0m for the financial year ended June 2008. Of the total increase, 7 percentage points were contributed by weak dollar value. The remaining growth was the result of an increased demand for oral pharmaceutical products. Oral Technologies' EBITDA increased 8.0% to \$236.3m in the financial year 2008.


#### Sterile Technologies

The Sterile Technologies segment registered strong performance with its revenues increasing 20.8% over the last financial year. The weaker dollar contributed only 5 percentage points. The remaining increase was contributed by volume increases in most of the sterile manufacturing facilities, including increased demand for flu vaccine products at the Belgium facility. EBITDA from Sterile Technologies increased from \$3.5m in financial year 2007 to \$25.7m in the financial year 2008.

#### Packaging Services

Packaging Services revenues decreased 3.7% to \$531.3m. Excluding favorable currency impact, the decline is 7.0%. This was primarily due to a fall in demand for packaging and printing services in North America. Packaging Services EBITDA declined 24.4%.

Figure 8.14: Parexel financial performance (\$m), 2004-08



Business Insights

Table 3.8: Catalent's business segments performance (\$m), 2006-2008

Segments	Revenues 2008	CAGR (%) 2006-08	EBITDA 2008
Oral Technologies	1,039.00	6.80%	236.3
Sterile Technologies	301	6.60%	25.7
Packaging Services	531.3	4.90%	61.9
Intersegment/ Adjustment	-43.3	-	-557.5
<b>Total</b>	<b>1,828.00</b>		<b>-233.6</b>

Business Insights

## Table of Contents

### CHAPTER 1: INTRODUCTION

- Methodology

### CHAPTER 2: MARKET DEVELOPMENT

- Overview
  - Market size and growth
  - Positioning and performance of leading players
  - Drivers of manufacturing outsourcing
  - Key trends in the market
  - Increasing offshore outsourcing by Big Pharma
  - Expansion of biopharmaceutical contract manufacturing
  - Industry consolidation
- Contract manufacturing hotspots – India and China
- India
  - Contract manufacturing in India
  - Key CMOs in India
- China
  - Contract Manufacturing in China
  - Key CMOs in China
- Comparison of India and China on key parameters
  - Availability of skilled labor
  - Cost
  - Manufacturing infrastructure
  - Global capabilities
  - Service portfolio
  - Concerns about offshoring

### CHAPTER 3: CATALENT

- Company overview
- Group structure
  - Oral Technologies
  - Sterile Technologies
  - Packaging Services

- Recent financial performance
  - Performance by business segments
  - Oral Technologies
  - Sterile Technologies
  - Packaging Services
  - Performance by geographies
- Manufacturing and R&D
- Acquisitions and divestments
- Growth strategies

### CHAPTER 4: LONZA

- Company overview
- Group structure
  - Life Science Ingredients
  - Exclusive Synthesis & Biopharmaceuticals
  - Bioscience
- Recent financial performance
  - Performance by business segments
- Manufacturing and R&D
- Acquisitions and divestments
- Growth strategies
  - Capacity expansion
  - Strategic partnerships and acquisitions
  - High value products

### CHAPTER 5: BOEHRINGER INGELHEIM (BI)

- Company overview
- Group structure
  - Biopharmaceuticals
  - Pharmaceuticals Production
  - Pharma Chemicals
- Recent financial performance
  - Performance by business segments
- Manufacturing and R&D
- Acquisitions and divestments

- Growth strategies
  - Capacity expansion
  - Strategic partnerships

### CHAPTER 6: ROYAL DSM (DSM)

- Company overview
- Group structure
- Recent financial performance
- Manufacturing and R&D
- Acquisitions and divestments
- Growth strategies

### CHAPTER 7: EVONIK (DEGUSSA)

- Company overview
- Group structure
- Recent financial performance
- Manufacturing and R&D
- Acquisitions and divestments
- Growth strategies
  - Restructuring of operations
  - Geographic restructuring
  - Capacity expansion
  - Geographic expansion

### CHAPTER 8: PATHEON

- Company overview
- Group structure
  - Commercial Manufacturing
  - Pharma Development Services (PDS)
- Recent financial performance
  - Performance by business segments
  - Performance by geographies
- Manufacturing and R&D
- Acquisitions and divestments
- Growth strategies
  - Focus on prescription drugs business
  - Improve profitability and capacity utilization
  - Diversify customer base

## Table of Contents

### CHAPTER 9: PIRAMAL

#### HEALTHCARE (PIRAMAL)

- Company overview
- Group structure
  - PDS (Pharmaceutical Development Services)
  - PMS (Pharmaceutical Manufacturing Services)
  - MMBB (Manufacturing Molecules/ Building Blocks)
  - Others
- Recent financial performance
  - Performance by business segments
- Manufacturing and R&D
- Acquisitions and divestments
- Growth strategies

### CHAPTER 10: JUBILANT ORGANOSYS (JUBILANT)

- Company overview
- Group structure
- Recent financial performance
  - Performance by product segments
  - Performance by geographies
- Manufacturing and R&D
- Acquisitions and divestments
- Growth strategies

### CHAPTER 11: AENOVA

- Company overview
- Group structure
  - Swiss Caps
  - Dragenopharm
- Recent financial performance
- Manufacturing and R&D
- Acquisitions and divestments
- Growth strategies

### CHAPTER 12: FAREVA

- Company overview
- Group structure
- Recent financial performance
- Manufacturing and R&D
- Acquisitions and divestments
- Growth strategies

### CHAPTER 13: 11 TO 20 COMPANIES

- **Nipro**
  - Company overview
  - Recent financial performance
- **Siegfried**
  - Company description
  - Recent financial performance
- **Haupt**
  - Company description
  - Recent financial performance
- **Divi's Laboratories (Divi's)**
  - Company description
  - Recent financial performance
- **Cambrex**
  - Company description
  - Recent financial performance
- **Recipharm**
  - Company description
  - Recent financial performance
- **Archimica**
  - Company description
- **Vetter**
  - Company description
- **Famar**
  - Company description
- **NextPharma**
  - Company description
- Other contract manufacturers
- Index

### LIST OF FIGURES

- Global pharmaceutical contract manufacturing market size, 2007-2011
- Positioning of leading players (2007)\*
- Labor cost in select countries
- No. of FDA approved plants outside the US, 2007
- Catalent's financial performance (\$m), 2004-2008\*
- Catalent's revenue break-up by geography (%), 2008
- Lonza's contract manufacturing financial performance (\$m), 2005-2007\*
- BI Industrial Customers' financial performance (\$m), 2005-2007\*
- DSM DPP's financial performance (\$m), 2005-2007\*
- Evonik's Health & Nutrition financial performance (\$m), 2006-2007\*
- Patheon's financial performance (\$m), 2006-2008\*
- Patheon's Commercial Manufacturing revenue break-up by geography (%), 2008\*
- Piramal Pharma Solutions' financial performance (\$m), 2006-2007\*
- Jubilant's CRAMS financial performance (\$m), 2003-2007\*
- Jubilant's revenue break-up by geography (%), 2007\*
- Fareva Pharmaceuticals' financial performance (\$m), 2006-2008\*

## Table of Contents

### LIST OF TABLES

- Leading pharmaceutical contract manufacturing companies, 2007
- Select manufacturing outsourcing initiatives planned by the Big Pharma
- Leading CMOs in India
- Select foreign acquisitions by Indian players
- Manufacturing cost comparison
- Catalent's snapshot
- Catalent's financial performance (\$m), 2004-2008
- Catalent's business segments performance (\$m), 2006-2008
- Catalent's performance by geography (\$m), 2006-2008
- Lonza's snapshot
- Lonza's contract manufacturing financial performance (\$m), 2005-2007
- Lonza's contract manufacturing business segments performance (\$m), 2005-2007
- BI's snapshot
- BI Industrial Customers' financial performance (\$m), 2005-2007
- BI Industrial Customers' business segments performance (\$m), 2005-2007
- DSM's snapshot
- DSM DPP's financial performance (\$m), 2005-2007
- Evonik's snapshot
- Evonik's Health & Nutrition financial performance (\$m), 2006-2007
- Patheon's snapshot
- Patheon's financial performance (\$m), 2006-2008
- Patheon's business segments performance (\$m), 2008
- Patheon's Commercial Manufacturing performance by geography (\$m), 2007-2008
- Piramal's snapshot
- Piramal Pharma Solutions' financial performance (\$m), 2006-2007
- Piramal Pharma Solutions' business segments performance (\$m), 2005-2007
- Jubilant's snapshot
- Jubilant's CRAMS financial performance (\$m), 2003-2007
- Jubilant's CRAMS product segments performance (\$m), 2006-2007
- Jubilant's performance by geography (\$m), 2005-2007
- Aenova's snapshot
- Fareva's snapshot
- Fareva Pharmaceuticals' financial performance (\$m), 2006-2008
- Nipro's snapshot
- Nipro's Pharmaceutical financial performance (\$m), 2003-2007 \*
- Siegfried's snapshot
- Siegfried's financial performance (\$m), 2006-2007\*
- Haupt's snapshot
- Divi's' snapshot
- Divi's financial performance (\$m), 2003-2007
- Cambrex's snapshot
- Cambrex's financial performance (\$m), 2005-2007\*
- Recipharm's snapshot
- Recipharm's financial performance (\$m), 2003-2008
- Archimica's snapshot
- Vetter's snapshot
- Famar's snapshot
- NextPharma's snapshot
- Other select contract manufacturers